Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 10;12(6):e060272.
doi: 10.1136/bmjopen-2021-060272.

Acceptance commitment therapy (ACT) for psychological distress associated with inflammatory bowel disease (IBD): protocol for a feasibility trial of the ACTforIBD programme

Subhadra Evans  1 , Lisa Olive  2 , Madeleine Dober  3 , Simon Knowles  4 , Matthew Fuller-Tyszkiewicz  3 , Eric O  5 , Peter Gibson  6 , Leanne Raven  7 , Richard Gearry  8 , Andrew McCombie  9 , Leesa van Niekerk  10 , Susan Chesterman  2 , Daniel Romano  2 , Antonina Mikocka-Walus  11
Affiliations

Acceptance commitment therapy (ACT) for psychological distress associated with inflammatory bowel disease (IBD): protocol for a feasibility trial of the ACTforIBD programme

Subhadra Evans et al. BMJ Open. .

Abstract

Introduction: Inflammatory bowel disease (IBD) involves an abnormal immune response to healthy gut bacteria. When a person develops IBD, their susceptibility to anxiety and/or depression increases. The ACTforIBD programme, specifically designed for people with IBD and comorbid psychological distress, draws on acceptance and commitment therapy (ACT), which promotes acceptance of situations that cannot be solved such as persistent physical symptoms. There are no ACT trials for IBD using an active control group or a telemedicine approach, which is important to improve accessibility, particularly in the context of the ongoing COVID-19 pandemic. The ACTforIBD programme is administered online with a 4-hour therapist involvement per participant only; if successful it can be widely implemented to improve the well-being of many individuals with IBD.

Methods and analysis: Our team have codesigned with consumers the ACTforIBD programme, an 8-week intervention of 1-hour sessions, with the first three sessions and the last session delivered one-to-one by a psychologist, and the other sessions self-directed online. This study aims to evaluate the feasibility and preliminary efficacy of ACTforIBD to reduce psychological distress in patients with IBD. Using a randomised controlled trial, 25 participants will be randomised to ACTforIBD, and 25 patients to an active control condition.

Ethics and dissemination: This protocol has been approved by Deakin University Research Ethics Committee in September 2021 (Ref. 2021-263) and the New Zealand Central Health and Disability Ethics Committee in December 2021 (Ref. 2021 EXP 11384). The results of this research will be published in peer-reviewed journals and shared with various stakeholders, including community members, policy-makers and researchers, through local and international conferences.

Trial registration number: ACTRN12621001316897.

Keywords: Adult gastroenterology; Inflammatory bowel disease; PSYCHIATRY.

PubMed Disclaimer

Conflict of interest statement

Competing interests: We do not have any conflicts of interest in relation to the present study, however, outside this work, SK has served as an educational speaker for Janssen, Ferring and Takeda. PG has served as a speaker, a consultant and an advisory board member for Allergan, Janssen, MSD, Pfizer, Anatara, Atmo Biosciences, Immunic Therapeutics, Novozymes and Takeda and Bristol-Meyers Squibb, and has received research funding from from MSD and Atmo Biosciences; and RG owns stocks and shares in Atmo Biosciences. LR served on the Roche International Patient Advisory Council and the Takeda IBD Patient Expert Council. RG has served on advisory boards for AbbVie New Zealand and Australia, Zespri New Zealand and Jannsen New Zealand and has received research funding from AbbVie. AM-W has served as an educational speaker for Janssen and Ferring.

References

    1. Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med 2020;383:2652–64. 10.1056/NEJMra2002697 - DOI - PubMed
    1. CentreforDiseaseControlandPrevention . Inflammatory bowel disease prevalence (IBD) in the United States: centre for disease control and prevention, 2019. Available: https://www.cdc.gov/ibd/data-statistics.htm
    1. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56–66. 10.1038/s41575-020-00360-x - DOI - PMC - PubMed
    1. Gracie DJ, Guthrie EA, Hamlin PJ, et al. Bi-Directionality of brain-gut interactions in patients with inflammatory bowel disease. Gastroenterology 2018;154:1635–46. 10.1053/j.gastro.2018.01.027 - DOI - PubMed
    1. Mikocka-Walus A, Knowles SR, Keefer L, et al. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis 2016;22:752–62. 10.1097/MIB.0000000000000620 - DOI - PubMed

Publication types

LinkOut - more resources